Omeros (OMER) Q2 2026 Earnings Call Transcript
Omeros reported strong Q2 2026 results with Yartemlia gross sales reaching $32.2 million, a 190% increase from the previous quarter, driven by significant adoption in adult transplant centers. The company achieved positive operating cash flow of $4.1 million and strengthened its capital structure through share and note repurchases, reducing outstanding debt by 43%. Despite a negative opinion from the European Medicines Agency on Yartemlia's marketing application, Omeros is pursuing reexamination and continues to advance its MASP-2 platform and other development programs.
Omeros stock hits 52-week high at 18.16 USD
Omeros Corporation's stock reached a new 52-week high of $18.16, pushing its market capitalization to $1.31 billion, despite InvestingPro data suggesting it might be overvalued. This surge, representing a 327.45% increase over the past year, follows positive financial results for the second quarter, including adjusted earnings of $0.02 per share and $28.5 million in revenue, significantly exceeding analyst expectations, largely due to the successful launch of their drug YARTEMLEA. The stock's RSI indicates it is in overbought territory.
Omeros director Joseph L. Schocken files initial beneficial ownership statement
Omeros director Joseph L. Schocken has filed an initial SEC Form 3, disclosing beneficial ownership of 528,082 common shares. This information, dated August 12, was generated by Public Technologies (PUBT) using AI and is based on content originally published by Omeros Corporation via EDGAR on August 18, 2026.
Why Omeros (OMER) Is Up 27.5% After Swinging To Profitability And Completing Share Buyback
Omeros Corporation (OMER) saw its stock price jump 27.5% after reporting a swing to profitability in Q2 and half-year 2026, with net incomes of US$13.23 million and US$69.29 million respectively. The company also completed a share buyback of 843,187 shares and expanded its board, including the addition of Joseph Schocken, to strengthen governance. These developments, along with its pipeline advancements and a US$142.67 million ESOP-related shelf registration, are expected to influence its investment narrative, though the company's reliance on its YARTEMLEA drug remains a key focus for investors.
Omeros Appoints Veteran Investor Joseph Schocken to Board
Omeros Corporation has expanded its Board of Directors to nine members by appointing veteran investor Joseph Schocken. Schocken, founder of Broadmark Capital and instrumental in the JOBS Act, will also serve on the Audit Committee and has been granted stock options. This move aims to leverage his capital markets and policy expertise, with an analyst rating Omeros stock as a Buy with a $33.00 price target.
Omeros Corporation (NASDAQ:OMER) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Omeros Corporation (NASDAQ:OMER) has received a "Moderate Buy" consensus recommendation from brokerages, with an average 12-month price target of $38.00, significantly higher than its recent share price of $17.19. The company recently exceeded Q2 earnings expectations, reporting $0.02 EPS against an anticipated $0.27 loss, driven by a strong YARTEMLEA launch and debt reduction. Despite positive momentum, analysts have slightly trimmed longer-term EPS forecasts, and a director recently sold a portion of his shares.
Omeros: YARTEMLEA Is Off To A Blistering Start (NASDAQ:OMER)
Omeros Corporation has received a Buy rating due to YARTEMLEA's unexpectedly strong launch, generating $28.5 million in net sales and positive operating cash flow in its first full quarter. The drug's adoption is rapidly increasing across transplant centers, with high formulary approval rates and growing adult patient usage, confirming its commercial potential. Additionally, Omeros has improved its capital structure by reducing convertible debt and initiating share repurchases, lessening dilution risk and future interest expenses.
Omeros Corporation $OMER Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Omeros Corporation (NASDAQ:OMER) by 85.2% in the first quarter, now holding 179,594 shares valued at $1.9 million. This comes as Omeros recently reported strong Q2 earnings, beating analyst expectations with $0.02 EPS and $28.53 million in revenue. Despite some recent analyst downgrades, the stock maintains a "Moderate Buy" consensus rating with a $38 average price target, driven by positive sales momentum and financial initiatives.
Omeros Corp Swings To Q2 Profit On YARTEMLEA Momentum; Plans ARDS, TA-TMA Studies; Shares Rise
Omeros Corporation reported a swing to profit in Q2 2026, driven by significant revenue growth from its YARTEMLEA sales. The company also announced plans to initiate two new studies for YARTEMLEA by the end of 2026, targeting hyperinflammatory acute respiratory distress syndrome (ARDS) and prophylactic use in pediatric TA-TMA patients. Omeros shares rose following the announcement, reflecting positive investor response to its financial performance and pipeline developments.
OMEROS CORP SEC Filing (Aug 13, 2026)
This article details an SEC Form 144 filing by Omeros Corp (OMER) on August 13, 2026. The filing indicates a proposed sale of 5,000 shares of common stock, valued at $68,550.00, resulting from the exercise of stock options. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ.
Top trending stocks today: ARX, OMER, TMS lead the market movers
Accelerant Holdings (ARX), Omeros Corporation (OMER), and Teamshares Inc. (TMS) were among the top trending stocks, experiencing significant surges due to major news or earnings momentum. Accelerant Holdings saw a 43.2% jump after an announced all-cash buyout, Omeros Corporation rose 24.5% following impressive Q2 results and positive cash flow, and Teamshares Inc. climbed 24.4% driven by strong analyst sentiment. Other companies like ERock, BBB Foods, Sandisk, and Aveanna Healthcare also showed strong gains, highlighting the impact of buyouts, earnings, and tech sector momentum on stock performance.
Omeros Corporation reports results for the quarter ended June 30 - Earnings Summary
Omeros Corporation has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters, provides a concise overview of the company's financial performance during this period. Readers can access the full report for detailed insights into the results.
Omeros Corporation (NASDAQ: OMER) turns profitable as YARTEMLEA sales ramp
Omeros Corporation (NASDAQ: OMER) reported a significant return to profitability in Q2 2026, driven by $28.5 million in product sales from its newly launched drug YARTEMLEA. The company achieved a net income of $13.2 million for the quarter and $69.3 million for the first half of 2026, a substantial improvement from prior year losses. Despite positive earnings, Omeros recorded negative operating cash flow for the first half of 2026 and faces significant OMIDRIA royalty and convertible note obligations.
Omeros surges 13% on strong earnings and revenue beat
Omeros Corporation (NASDAQ:OMER) reported second-quarter results that significantly surpassed analyst expectations, driven by strong sales of its new TA-TMA treatment, YARTEMLEA. The company posted adjusted earnings per share of $0.02 and revenue of $28.5 million, significantly beating estimates. Shares of Omeros surged 13% in after-hours trading following the positive results, with management expressing satisfaction with the drug's market acceptance.
BRIEF-Omeros Corporation Q2 EPS USD 0.18
Omeros Corporation reported Q2 EPS of USD 0.18. This brief announcement was made available via Reuters and highlighted on TradingView News.
Earnings Flash (OMER) Omeros Corporation Reports Q2 Revenue $28.5M, vs. FactSet Est of $12.7M
Omeros Corporation (OMER) announced Q2 revenue of $28.5 million, significantly surpassing FactSet's estimate of $12.7 million. The company, which is a clinical-stage biopharmaceutical firm, focuses on developing therapeutics for complement-mediated diseases, cancers, and addictive disorders. They also reported earnings results for the second quarter and six months ended June 30, 2026, and their commercial product, YARTEMLEA, is approved for TA-TMA treatment.
Press Release: Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation will announce its second quarter financial results on Wednesday, August 12, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the financial results and provide an update on recent developments.
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
Omeros Corporation will announce its second-quarter 2026 financial results on August 12, 2026, after market close. Management will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results and recent developments. The company is a biotechnology firm focused on developing therapeutics for various diseases, including complement-mediated conditions, cancers, and addictive disorders.
Omeros Corporation Revenue Breakdown – NASDAQ:OMER
This article provides an overview of Omeros Corporation (NASDAQ: OMER) financials on TradingView. It highlights the availability of financial statements, statistics, dividends, earnings, and segment performance data for the company. The content primarily acts as a directory to various financial insights offered by the TradingView platform for Omeros Corporation.
Omeros Corporation (OMER) Investigation: Bronstein, Gewirtz & Gro
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Omeros Corporation (NASDAQ: OMER) after its stock price fell significantly. This follows the European Medicines Agency's negative opinion on Omeros's marketing authorization application for narsoplimab, a drug intended to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm encourages investors who purchased Omeros securities to contact them for more information regarding the investigation.
Liquidity Mapping Around (OMER) Price Events
The article provides a detailed liquidity mapping analysis for Omeros Corporation (NASDAQ: OMER), highlighting strong sentiment across all horizons and an exceptional 94.5:1 risk-reward setup. It outlines three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide potential trades. The analysis suggests support is being tested, and if it holds, resistance will be the next target, offering a 28.8% gain versus 0.3% risk.
Liquidity Mapping Around (OMER) Price Events
This article provides a detailed liquidity mapping and trading strategy analysis for Omeros Corporation (NASDAQ: OMER) based on AI models. It highlights strong sentiment supporting an overweight bias, outlines specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry/target/stop loss levels, and presents a multi-timeframe signal analysis indicating strong support across all horizons.
Omeros (OMER) to Announce Quarterly Earnings on Thursday
Omeros (NASDAQ:OMER) is scheduled to release its Q2 2026 earnings after market close on Thursday, August 13th. Analysts anticipate a loss of $0.27 per share and revenues of $12.7 million. The company's stock, which recently traded near $12.65, currently holds a "Moderate Buy" consensus rating with an average price target of $38.
Omeros (NASDAQ:OMER) Shares Pass Above Two Hundred Day Moving Average - Here's What Happened
Omeros (NASDAQ:OMER) shares recently surpassed their two-hundred-day moving average, closing at $12.94 after reaching $13.05. The biopharmaceutical company reported better-than-expected quarterly earnings, with a loss of $0.24 per share against a projected $0.40 loss, and revenue of $9.89 million against a $4.19 million estimate. Analyst sentiment is mixed, holding a "Moderate Buy" consensus rating with a $38.00 target price, while insider transactions show a director recently sold a portion of their shares.
Medicare Hospitals Can Get Up to $287,079 to Treat a Transplant Complication
Omeros Corporation announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for its drug YARTEMLEA®. This status allows eligible hospitals to receive up to $287,079 in additional Medicare reimbursement per patient for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) with YARTEMLEA, effective October 1, 2026. The decision aims to reduce the financial burden on hospitals and ensure timely patient access to the FDA-approved treatment.
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug
Omeros Corporation (OMER) shares rose 4% after the U.S. Medicare officials approved additional payments of up to $287,000 for hospitals using its drug YARTEMLEA. This drug treats a rare and life-threatening complication of stem cell transplants, and the extra funds aim to help hospitals cover the high treatment cost. YARTEMLEA is Omeros' first commercial product, generating $9.9 million in Q1 sales, and is crucial for funding the company's research pipeline.
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
Omeros Corporation announced that the Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for YARTEMLEA® (narsoplimab-wuug), effective October 1, 2026. This status provides additional Medicare reimbursement to hospitals for treating eligible Medicare patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). YARTEMLEA is the only FDA-approved treatment for TA-TMA, a rare and life-threatening complication, and the NTAP status is expected to facilitate greater patient access by reducing the financial burden on hospitals.
OMER Stock Gains 4% — CMS Green-Lights $287K Add-On Payments For Transplant Drug
Omeros Corporation's stock (OMER) gained 4% after the U.S. Medicare officials approved additional payments to hospitals using its new drug, YARTEMLEA. Starting October 1, hospitals can receive up to $287,000 more from Medicare for each qualifying patient treated with YARTEMLEA, a drug for a rare stem cell transplant complication. This decision aims to ease cost concerns for hospitals and is expected to boost YARTEMLEA's sales, which are crucial for funding Omeros's research pipeline.
Omeros Corporation Revenue Breakdown – BX:3O8
This article provides a brief overview of Omeros Corporation (BX:3O8) financials, specifically focusing on its revenue breakdown. It indicates that further details on segments and regional performance can be found on TradingView, which sources data from ICE Data Services, FactSet, and Quartr.
Omeros Corporation Revenue Breakdown – HAM:3O8
This article provides details on Omeros Corporation's (HAM:3O8) financials, specifically its revenue breakdown. It lists various sections available on TradingView for the company, including an overview, financial statements, statistics, dividends, earnings, and segment performance. The content is primarily navigational and informational regarding what financial data points are accessible for Omeros Corporation on the platform.
BlackRock (OMER) discloses 5.96M Omeros Corp shares in amended 13G filing
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a beneficial ownership of 5,961,792 shares of Omeros Corp common stock, which represents an 8.2% stake in the company. BlackRock exercises sole voting power over 5,835,368 shares and sole dispositive power over all 5,961,792 shares, with no single client holding more than five percent of Omeros's outstanding common stock. This filing indicates that the shares are held for investment purposes in the ordinary course of business, rather than to influence control of the issuer.
OMER Stock News Today | Earnings, Events & Price Alerts
This article provides news and event updates for Omeros Corporation (OMER), including stock price movements and related market news. Key recent developments include a surge in Omeros shares following AstraZeneca's Ultomiris Phase 3 trial failure and reports of a securities fraud investigation into Omeros Corporation. The events section also covers broader market movements, economic data, and earnings from other companies, noting Omeros' stock increase after the AstraZeneca news.
Lawsuit probes Omeros over stock drop after EMA rejects drug approval
Pomerantz LLP is investigating Omeros Corporation for securities fraud following a significant 19.12% stock drop on June 26, 2026. This decline occurred after the European Medicines Agency issued a negative opinion regarding Omeros's drug narsoplimab. The investigation seeks to determine if Omeros misled investors about the drug's approval prospects, and affected investors are encouraged to contact the law firm.
H.C. Wainwright reiterates Omeros stock rating on rival trial miss
H.C. Wainwright maintained a Buy rating and $33.00 price target for Omeros Corp. (NASDAQ: OMER) after a competitor's clinical trial for Ultomiris/ravulizumab failed to meet its primary endpoint. This development reduces the competitive threat to Omeros's Yartemelea drug launch in the U.S., allowing investor focus to shift to its commercial execution and the broader value of its MASP-2 platform. The firm previously reiterated a Buy rating with a $40 price target, despite a recent setback with the European Medicines Agency's negative opinion on narsoplimab's marketing application.
Omeros Corp (OMER) Stock Score & Comprehensive Stock Analysis
TradingKey provides a comprehensive stock analysis for Omeros Corp (OMER), noting its stable fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. The company, focused on developing therapeutics for immunologic disorders and cancers, has high institutional ownership and four analysts recommending a "Buy" with a high target price. However, the analysis also indicates an expected downward trend in the medium term and sideways trading, making it suitable for range-bound swing trading.
Omeros Corporation Revenue Breakdown – LS:A0NBFF
This page provides financial information for Omeros Corporation (LS:A0NBFF) on TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment breakdowns by source and country. The content appears to be a stub or a section of a larger financial data platform.
AstraZeneca's Rare Disease Setback Is A 'Clear Positive' For Omeros, Says This Analyst – A Look At Some Key Highlights
H.C. Wainwright reiterated its 'Buy' rating on Omeros (OMER) after AstraZeneca's (AZN) Ultomiris failed its primary endpoint in a Phase 3 trial for transplant-associated thrombotic microangiopathy (TA-TMA). This setback is seen as a "clear positive" for Omeros, as it removes the primary near-term competitive threat to its FDA-approved drug, Yartemlea, improving its competitive positioning in the U.S. market, despite earlier European regulatory hurdles for Yartemlea.
Form 4 Omeros Corporation For: 24 July By Investing.com
This article from Investing.com reports that Omeros Corporation (OMER) filed a Form 4 for insider transactions on July 24. While the article title implies detailed content about the filing, the body of the article simply reiterates the filing information without providing specific transaction details. The stock symbol OMER is mentioned with a -4.77% change.
Form 4 Omeros Corporation For: 24 July By Investing.com
This article announces the filing of Form 4 for Omeros Corporation (OMER) for July 24th. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's stock by its directors, officers, or any shareholder owning more than 10% of the company's class of equity securities. The article does not provide details about the content of the Form 4.
Omeros stock trades around small-cap biotech levels as narsoziumab and OMS906 shape the pipeline out
Omeros Corporation, a small-cap biotech, is valued based on its legacy revenue from Omidria and the potential of its pipeline drugs narsoziumab and OMS906. While the company consistently reports operating losses due to high R&D investments, Omidria provides foundational revenue and experience, with significant future growth dependent on successful clinical and regulatory milestones for its complement-targeted therapies. The stock's valuation reflects investor anticipation for these pipeline developments.
OMER6080787 Bond Risk Profile
This page provides a risk profile for the OMER6080787 bond, issued by Omeros Corporation with a 9.5% coupon maturing on June 15, 2029. It outlines key metrics for credit risk assessment, including the bond's security level and issuer rating. Additionally, it offers access to analyst ratings and data from various financial service providers.
OMER6080787 Bond Coupon Profile — Rate & Payments
This article provides the bond coupon profile for Omeros Corporation's OMER6080787 bond. It details that the bond has a current coupon rate of 9.50% and the next interest payment is scheduled for December 15, 2026. The article highlights the importance of understanding coupon data for bonds.
Omeros faces securities fraud probe after EMA rejects key drug application, stock drops 19%.
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud after the European Medicines Agency (EMA) issued a negative opinion on its drug narsoplimab, causing a 19.12% stock drop on June 26, 2026. The probe is focused on unlawful business practices by Omeros and its officers. Affected investors are encouraged to contact Pomerantz LLP regarding possible class action participation.
Law firm probes Omeros over stock drop after EM...
Pomerantz LLP is investigating Omeros Corporation for potential securities fraud after the European Medicines Agency's negative opinion on their drug narsoplimab caused a nearly 20% stock drop on June 26, 2026. The investigation aims to determine if the company or its executives engaged in unlawful business practices.
OMER6081715 Bond Coupon Profile — Rate & Payments
This article provides the coupon profile for the Omeros Corporation bond OMER6081715, detailing its interest rate and payment schedule. The bond has a current coupon rate of 9.50%, with the next interest payment planned for December 15, 2026. The article highlights the importance of understanding bond coupons, which represent the interest rate paid on a bond, and offers to unlock more in-depth data.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Omeros Corporation (OMER) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Omeros Corporation (OMER) after the company announced a negative opinion from the CHMP regarding its marketing authorization application for narsoplimab. This news led to a significant drop in Omeros's stock price. The firm is encouraging affected shareholders to contact them for more information on the investigation.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
Pomerantz LLP is investigating potential securities fraud claims against Omeros Corporation (NASDAQ: OMER) following a significant drop in its stock price. The investigation stems from the European Medicines Agency's negative opinion on Omeros's marketing authorization application for narsoplimab, leading to a 19.12% stock decline. Investors are encouraged to contact Pomerantz LLP for more information regarding this potential class action.
Understanding Momentum Shifts in (OMER)
Omeros Corporation (OMER) is experiencing weak near-term sentiment despite long-term strength, with its support levels currently being tested. AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored to different risk profiles, along with multi-timeframe signal analysis indicating varying support and resistance levels across short, mid, and long horizons. An exceptional risk-reward setup targets a substantial gain for the stock.
Omeros stock drops 19% after EU rejects key drug application, prompting investor lawsuit.
Omeros Corporation's stock dropped 19.12% after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on its drug narsoplimab. This rejection led to Pomerantz LLP launching a securities fraud investigation on behalf of Omeros investors, citing potential misconduct by the company. The outcome is expected to affect investor confidence and future drug approval processes for the company.
Omeros Corporation Investigated by the Portnoy Law Firm
The Portnoy Law Firm has launched an investigation into Omeros Corporation (NASDAQ: OMER) for potential securities fraud and may file a class action lawsuit. This follows a significant 19.12% drop in Omeros's stock price after the European Medicines Agency's committee issued a negative opinion on their marketing authorization application for narsoplimab. Investors affected by this disclosure are encouraged to contact the firm.
